| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2973243 | The Journal of Heart and Lung Transplantation | 2006 | 6 Pages |
Abstract
Tac and mCyA appear to be comparable with regard to 5-year survival, freedom from rejection and CAV. However, compared with mCyA, Tac appears to reduce the adverse effect profile for hypertriglyceridemia and renal dysfunction and the need for hypertensive medications.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jon A. MD, J. MD, PhD, H. MD, J.D. MD, L. Yeatman, S. PhD, A. BA, J. BS, B.T. MPH, S. MD, G.W. BAS, J. BA, H. MD,